达格列净联合胰岛素强化治疗对2型糖尿病 患者对改善血糖和不良反应的效果

Effect of Dapagliflozin Combined with Intensive Insulin Therapy on Improving Blood Glucose and Adverse Reactions in Patients with Type 2 Diabetes

摘要: 目的：探究2型糖尿病(Type 2 Diabetes Mellitus, T2DM)患者应用达格列净联合胰岛素强化治疗的效果。方法：将我院自2024年1月~2024年12月收治的168例T2DM患者纳入研究。根据治疗方法不同分为研究组(n = 84)、基础组(n = 84)。基础组给予胰岛素强化治疗，研究组加用达格列净治疗。比较两组相关指标。结果：研究组血糖水平中空腹血糖(6.85 ± 1.13 vs 8.87 ± 1.18) mmol/L、餐后2 h血糖(8.09 ± 1.05 vs 10.20 ± 1.15) mmol/L和糖化血红蛋白(6.75 ± 0.85 vs 7.81 ± 0.81)%水平均低于基础组(t = 11.332, 12.418, 8.274; P < 0.05)；研究组血脂水平中甘油三酯、总胆固醇及脂联素水平均优于基础组(P < 0.05)；研究组胰岛功能中空腹胰岛素、胰岛细胞功能指数和胰岛素抵抗指数水平均优于基础组(P < 0.05)；两组不良反应情况比较无差异(P > 0.05)。结论：两种治疗方法联合治疗能够改善T2DM患者的血糖、血脂水平和胰岛功能，安全性较好。

Abstract: Objective: To explore the effect of intensive treatment of dapagliflozin combined with insulin in patients with type 2 diabetes (T2DM). Method: 168 T2DM patients admitted to our hospital from January 2024 to December 2024 were included in the study. According to different treatment methods, they were divided into a study group (n = 84) and a basic group (n = 84). The basic group received intensive insulin therapy, while the study group received additional treatment with dapagliflozin. Compare two sets of related indicators. Result: The fasting blood glucose (6.85 ± 1.13 vs 8.87 ± 1.18) mmol/L, postprandial 2-hour blood glucose (8.09 ± 1.05 vs 10.20 ± 1.15) mmol/L, and glycated hemoglobin (6.75 ± 0.85 vs 7.81 ± 0.81)% levels in the study group were all lower than those in the baseline group (t = 11.332, 12.418, 8.274; P < 0.05); the levels of triglycerides, total cholesterol, and adiponectin in the study group were higher than those in the baseline group (P < 0.05); the levels of fasting insulin, pancreatic islet cell function index, and insulin resistance index in the study group were superior to those in the baseline group (P < 0.05); there was no difference in adverse reactions between the two groups (P > 0.05). Conclusion: The combination of two treatment methods can improve the blood glucose, lipid levels, and pancreatic function of T2DM patients with good safety.